A Clinician's guide to vitamin D supplementation for patients with cystic fibrosis.
Vitamin D deficiency is common in the general population, and even more so in patients with cystic fibrosis. Deficiency is exacerbated in cystic fibrosis patients because of a myriad of causes including malabsorption, decreased fat mass, reduced 25-hydroxylation of vitamin D, reduced exposure to sunlight, decreased vitamin D binding protein, and exposure to drugs that increase catabolism. In turn, vitamin D deficiency can contribute to poor bone health. Additionally, it may contribute to pulmonary decline in the form of worsening pulmonary function, increased colonization with pathogens, and increased pulmonary exacerbation. Because vitamin D deficiency is correlated with negative clinical effects in multiple organ systems of patients with cystic fibrosis, it is important to screen for and treat deficiency in these patients. The Cystic Fibrosis Foundation has issued guidelines for the treatment of vitamin D deficiency, targeting serum levels of 25-hydroxyvitamin D of at least 30 ng/ml. The guidelines offer age-specific escalating dose regimens depending on serum vitamin D levels, with monitoring at 12- week intervals after changing therapy. They address the literature on alternative vitamin D sources, such as UV lamps, ideal formulations (cholecalciferol in preference to ergocalciferol), and optimal vehicles of administration. Despite these detailed recommendations, most centers are still unable to achieve in-target serum vitamin D levels for many of their patients. Future research examining ideal treatment regimens to achieve serum targets and maximize clinical effects are needed. Moreover, it is unknown whether vitamin D sufficiency will be easier to achieve on new triple therapy cystic fibrosis drug combinations, and how these drugs will contribute to vitamin D-related clinical outcomes.
['Wood|Colleen|C|', 'Hasan|Sana|S|', 'Darukhanavala|Amy|A|', 'Tangpricha|Vin|V|']
Vitamin D Supplementation Cystic fibrosis Treatment Cholecalciferol 25(OH)D, 25-hydroxyvitamin D BMD, bone mineral density CF, cystic fibrosis CFRD, cystic fibrosis-related diabetes CFTR, cystic fibrosis transmembrane conductance regulator D2, ergocalciferol D3, cholecalciferol Metabolism NTM, nontuberculous mycobacteria PTH, parathyroid hormone RTC, randomized control trial Review